Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Rheumatology

Treating LV: The Path to Healing

At a Glance

Livedoid Vasculopathy (LV) is treated primarily with anticoagulants like rivaroxaban because it is caused by blood clots, not inflammation. While pain may improve quickly on blood thinners, healing skin ulcers takes weeks or months, and consistent treatment is needed to prevent relapses.

Treating Livedoid Vasculopathy (LV) requires a different strategy than treating many other skin conditions. Because LV is a thrombo-occlusive disease—meaning it is caused by blood clots, not primarily by inflammation—the “standard” treatments for rashes, such as high-dose steroids, are often ineffective for long-term management [1][2]. The goal of treatment is to stop new clots from forming, allow existing ulcers to heal, and provide significant pain relief [3][4].

The First Line: Stopping the Clots

The foundation of LV treatment is preventing the formation of fibrin clots in the small vessels of the skin [1][5].

Anticoagulants (Blood Thinners)

Anticoagulants are widely considered the most effective first-line therapy for LV [3][6].

  • Rivaroxaban: This is often the preferred choice because it is an oral pill that does not require the frequent blood monitoring associated with older blood thinners [3][7]. It has been shown to rapidly reduce pain and promote the healing of stubborn ulcers [4][8].
  • Low-Molecular-Weight Heparin (Enoxaparin): Sometimes used as an injection, especially during severe flare-ups or during pregnancy, to provide quick anticoagulation [9].
  • Antiplatelets: Medications like Aspirin or Dipyridamole may be used, sometimes in combination with other treatments, to keep blood cells from sticking together [5][1].

⚠️ Important Safety Warning: Bleeding Risks

Because anticoagulants work by reducing the blood’s ability to clot, their primary and most dangerous side effect is an increased risk of bleeding. When taking these medications, you must be vigilant. Seek emergency medical care immediately if you experience:

  • Blood in your stool (which may look bright red or like black, sticky tar).
  • Urine that is pink, red, or brown.
  • Severe bruising that expands quickly or happens without a known cause.
  • Nosebleeds that will not stop after 10 minutes of pressure.
  • Any significant fall or blow to the head, even if you feel fine, as internal bleeding can occur.

Why Not Steroids?

While systemic corticosteroids (like Prednisone) might provide temporary relief because they have a slight effect on blood vessel function, they are generally considered a “red flag” if used as the only treatment for the vessel clotting [2][10]. Steroids do not fix the underlying clotting problem, and symptoms often return immediately once the dose is lowered [11][2]. (Note: If your blood work reveals a concurrent autoimmune condition like Lupus, your rheumatologist may still properly prescribe steroids to manage that specific disease).

Setting Expectations: The Timeline to Healing

It is normal to want immediate relief, but healing from LV takes time.

  • Pain Reduction: The intense, “ischemic” pain might begin to improve rapidly—sometimes within a few days or weeks of starting effective anticoagulation [4].
  • Ulcer Closure: The actual closing and healing of the skin ulcers can take weeks or even months. Progress requires patience and consistent wound care.

Moving Up the “Therapeutic Ladder”

If first-line blood thinners are not enough to control the disease, your doctor may suggest moving to more advanced therapies. This is often necessary for “refractory” cases—those that don’t respond to standard care [12][13].

  1. JAK Inhibitors: Medications like baricitinib or tofacitinib are an emerging and promising option [14][8]. Recent research has found that certain inflammatory pathways (JAK-STAT) are active in LV skin lesions, and these drugs can help “calm” the vessel environment when anticoagulants alone aren’t enough [15][16].
  2. Intravenous Immunoglobulin (IVIG): This treatment involves infusions of antibodies that can help “reset” the vascular environment. It is often reserved for very severe cases or when other treatments have failed [17][18].
  3. Biologics (Anti-TNF agents): Drugs like adalimumab or etanercept, which are common in treating conditions like rheumatoid arthritis, have been used in LV to reduce vessel injury and provide rapid pain relief [19][20].

Consistency is Key

Because LV is a chronic condition, many patients need to stay on their treatment long-term to prevent new flares [3][21]. Stopping treatment as soon as an ulcer heals often leads to a recurrence. Your care team will work with you to find the lowest effective dose that keeps your skin clear and your pain managed while keeping you safe from bleeding [3][22].

Common questions in this guide

Why are anticoagulants used to treat Livedoid Vasculopathy instead of steroids?
Livedoid vasculopathy is caused by blood clots forming in the small vessels of the skin, not primarily by inflammation. Anticoagulants stop new clots from forming, whereas steroids do not fix this underlying clotting problem and symptoms often return once the steroid dose is lowered.
How long does it take for Livedoid Vasculopathy ulcers to heal?
While the intense pain may begin to improve within a few days or weeks of starting effective anticoagulation, the actual closing and healing of the skin ulcers can take weeks or even months. Patience and consistent wound care are essential for full recovery.
What are the warning signs of bleeding while on blood thinners for LV?
The primary risk of taking anticoagulants is an increased chance of bleeding. You should seek emergency medical care if you experience blood in your stool or urine, severe bruising, nosebleeds that will not stop after 10 minutes, or any significant fall.
What happens if standard blood thinners don't heal my LV ulcers?
If your ulcers do not improve with standard blood thinners, your doctor may suggest advanced therapies for refractory LV. These can include JAK inhibitors, intravenous immunoglobulin (IVIG), or biologics to help calm the blood vessel environment and promote healing.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given that LV is a clotting problem, why is an anticoagulant like rivaroxaban a better long-term choice for me than steroids?
  2. 2.What is the plan if my ulcers don't show improvement after 4–6 weeks of first-line therapy?
  3. 3.What specific signs of bleeding should prompt me to go to the emergency room?
  4. 4.What are the potential side effects of long-term blood thinner use that I should watch for?
  5. 5.If my pain remains severe, could I be a candidate for adjunctive treatments like JAK inhibitors or IVIG?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (22)
  1. 1

    Lymphocytic vasculitis in livedoid vasculopathy: A report of 137 cases.

    Yuan Y, Liu Y, Ban F, et al.

    Journal of cutaneous pathology 2024; (51(2)):155-162 doi:10.1111/cup.14546.

    PMID: 37837185
  2. 2

    Retiform non-blanchable purpuric plaques in a patient with systemic lupus erythematosus.

    Grinnell M, Bath A, DiMaio D, et al.

    Lupus 2019; (28(8)):1013-1016 doi:10.1177/0961203319847274.

    PMID: 31126212
  3. 3

    Long-Term Efficacy of Guideline-Followed Treatment in Patients with Livedoid Vasculopathy: A Single-Center Study.

    Hillgruber C, Mitschang C, Eveslage M, et al.

    Advances in wound care 2025; doi:10.1177/21621918251395013.

    PMID: 41264385
  4. 4

    Treatment outcomes in patients of livedoid vasculopathy following antithrombotic therapy: A retrospective observational study.

    Gupta P, Thakur V, Behera B, et al.

    Indian journal of dermatology, venereology and leprology 2026; 1-9.

    PMID: 41655089
  5. 5

    Pain Management Options in a Patient with Livedoid Vasculopathy and Peripheral Neuropathy.

    Palanisamy N, Chinnappan J, Bachuwa G

    European journal of case reports in internal medicine 2023; (10(1)):003727 doi:10.12890/2023_003727.

    PMID: 36819654
  6. 6

    Associations between coagulation factors and livedoid vasculopathy and the efficacy and safety of rivaroxaban in patients with livedoid vasculopathy: a retrospective study.

    Zhao C, Yu M, Cheng X, et al.

    Clinical and experimental dermatology 2024; (49(8)):817-824 doi:10.1093/ced/llae023.

    PMID: 38287670
  7. 7

    Anticoagulation with rivaroxaban for livedoid vasculopathy (RILIVA): a multicentre, single-arm, open-label, phase 2a, proof-of-concept trial.

    Weishaupt C, Strölin A, Kahle B, et al.

    The Lancet. Haematology 2016; (3(2)):e72-9.

    PMID: 26853646
  8. 8

    Baricitinib Successfully Treated a Teenager with Refractory Livedoid Vasculopathy: A Case Report and Literature Review.

    Liu C, Jin YY, Han X, et al.

    Journal of inflammation research 2025; (18()):1471-1477 doi:10.2147/JIR.S495481.

    PMID: 39925926
  9. 9

    Prevention of livedoid vasculopathy recurrence by prolonged administration of rivaroxaban.

    Drerup C, Goerge T

    Journal of the European Academy of Dermatology and Venereology : JEADV 2017; (31(12)):e532 doi:10.1111/jdv.14404.

    PMID: 28609556
  10. 10

    Refractory livedoid vasculopathy successfully treated with baricitinib.

    Xiao Y, Wang Y, Gu Y, et al.

    International journal of dermatology 2023; (62(9)):1204-1205 doi:10.1111/ijd.16467.

    PMID: 36349427
  11. 11

    Successful Treatment of Livedoid Vasculitis with Primary Antiphospholipid Syndrome by Using Aspirin and Low Dose Warfarin Combination Therapy.

    So BJ, Park JB, Yoo MG, et al.

    Annals of dermatology 2015; (27(5)):614-5 doi:10.5021/ad.2015.27.5.614.

    PMID: 26512179
  12. 12

    Livedoid vasculopathy.

    Leeolou MC, Rieger KE, Yeh JE

    Dermatology online journal 2023; (29(5)) doi:10.5070/D329562414.

    PMID: 38478650
  13. 13

    Treatment for Livedoid Vasculopathy: A Systematic Review.

    Micieli R, Alavi A

    JAMA dermatology 2018; (154(2)):193-202 doi:10.1001/jamadermatol.2017.4374.

    PMID: 29141075
  14. 14

    Differential response to Janus kinase inhibitors in refractory livedoid vasculopathy: Biomarker-guided therapy may improve clinical response.

    Yu G, Zhu J, Zhang Y, et al.

    JAAD international 2026; (24()):318-319 doi:10.1016/j.jdin.2025.11.024.

    PMID: 41561208
  15. 15

    Treatment of Livedoid Vasculopathy with the Janus Kinase Inhibitors: A Case Series.

    Zhao G, Liu Y, Ni J, Song Z

    Case reports in dermatology 2026; (18(1)):36-44 doi:10.1159/000549494.

    PMID: 41541192
  16. 16

    Baricitinib is potentially effective in the treatment of refractory livedoid vasculopathy.

    Han Y, Tu P

    Frontiers in immunology 2022; (13()):1008392 doi:10.3389/fimmu.2022.1008392.

    PMID: 36389811
  17. 17

    Autoimmune-Associated Livedoid Vasculopathy: Response to Immunomodulatory Therapy.

    Aung T, Cheah JX

    Cureus 2025; (17(9)):e92748 doi:10.7759/cureus.92748.

    PMID: 41122575
  18. 18

    Clinical and patient reported treatment outcomes of livedoid vasculopathy: a systematic review.

    Gipple MO, Throckmorton SK, Gabo VB, et al.

    Clinical and experimental dermatology 2025; (50(4)):856-858 doi:10.1093/ced/llae377.

    PMID: 39298646
  19. 19

    Adalimumab in Treating Refractory Livedoid Vasculopathy.

    Huang XW, Zheng HX, Wang ML, et al.

    Vaccines 2022; (10(4)) doi:10.3390/vaccines10040549.

    PMID: 35455298
  20. 20

    Efficacy of an anti-TNF-alpha agent in refractory livedoid vasculopathy: a retrospective analysis.

    Gao Y, Jin H

    The Journal of dermatological treatment 2022; (33(1)):178-183 doi:10.1080/09546634.2020.1737634.

    PMID: 32116074
  21. 21

    Livedoid vasculopathy - A diagnostic and therapeutic challenge.

    Burg MR, Mitschang C, Goerge T, Schneider SW

    Frontiers in medicine 2022; (9()):1012178 doi:10.3389/fmed.2022.1012178.

    PMID: 36262273
  22. 22

    Rivaroxaban for treatment of livedoid vasculopathy: A systematic review.

    Gao Y, Jin H

    Dermatologic therapy 2021; (34(5)):e15051 doi:10.1111/dth.15051.

    PMID: 34197012

This page explains Livedoid Vasculopathy treatment options for educational purposes. Always consult your healthcare provider before starting or stopping any medications, especially blood thinners.

Get notified when new evidence is published on Livedoid vasculopathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.